Modelling and PBPK simulation in drug discovery

AAPS Journal

Volumn 11, Issue 1, 2009, Pages 155-166

  Jones, Hannah M ^a   Gardner, Iain B ^a   Watson, Kenny J ^a  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

Author keywords

Absorption; Clearance; Distribution; PBPK; Pharmacokinetics

Indexed keywords

ALPRENOLOL; DICLOFENAC; DILTIAZEM; FELODIPINE; KETOCONAZOLE; METOPROLOL; NICARDIPINE; OMEPRAZOLE; PHENYTOIN;

ACCURACY; AREA UNDER THE CURVE; ARTICLE; COMPUTER MODEL; COMPUTER PREDICTION; COMPUTER PROGRAM; COMPUTER SIMULATION; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG METABOLISM; DRUG PENETRATION; DRUG RESEARCH; DRUG TISSUE LEVEL; HUMAN; MAXIMUM PLASMA CONCENTRATION; NONHUMAN;

ADMINISTRATION, ORAL; ALGORITHMS; ANIMALS; COMPUTER SIMULATION; DRUG DISCOVERY; HUMANS; INJECTIONS, INTRAVENOUS; INTESTINAL ABSORPTION; MODELS, BIOLOGICAL; OSMOLAR CONCENTRATION; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS; RATS; SOFTWARE; SPECIES SPECIFICITY; TISSUE DISTRIBUTION;

EID: 65549096369     PISSN: 15507416     EISSN: None     Source Type: Journal    
DOI: 10.1208/s12248-009-9088-1     Document Type: Article

References (63)

1. H. Boxenbaum. Interspecies scaling, allometry, physiological time, and the ground plan of pharmacokinetics. J. Pharmacokinet. Biopharm. 10:201-227 (1982).
2. I. Mahmood, and J. D. Balian. Interspecies scaling: Predicting pharmacokinetic parameters of antiepileptic drugs in humans from animals with special emphasis on clearance. J. Pharm. Sci. 85:411-414 (1996).
3. R. S. Obach, J. G. Baxter, T. E. Liston, B. M. Silber, B. C. Jones, F. MacIntyre, D. J. Rance, and P. Wastall. The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data. J. Pharmacol. Exp. Ther. 283:46-58 (1997).
4. T. Lave, P. Coassolo, and B. Reigner. Prediction of hepatic metabolic clearance based on interspecies allometric scaling techniques and in vitro - in vivo correlations. Clin. Pharmacokinet. 36:211-231 (1999a).
5. C. Tanaka, R. Kawai, and M. Rowland. Dose-dependent pharmacokinetics of cyclosporin A in rats: Events in tissues. Drug Metab. Dispos. 28:582-589 (2000).
6. I. Nestorov. Whole body pharmacokinetic models. Clin. Pharmacokinet. 42:883-908 (2003).
7. J. B. Houston. Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance. Biochem. Pharmacol. 47:1469-1479 (1994).
8. T. Iwatsubo, N. Hirota, T. Ooie, H. Suzuki, N. Shimada, K. Chiba, T. Ishizaki, C. E. Green, C. A. Tyson, and Y. Sugiyama. Prediction of in vivo drug metabolism in the human liver from in vitro metabolism data. Pharmacol. Ther. 73:147-171 (1997).
9. T. Lave, S. Dupin, C. Schmitt, B. Valles, G. Ubeaud, R. C. Chou, D. Jaeck, and P. Coassolo. The use of human hepatocytes to select compounds based on their expected hepatic extraction ratios in humans. Pharm. Res. 14:152-155 (1997).
10. R. S. Obach. Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: An examination of in vitro half-life approach and nonspecific binding to microsomes. Drug Metab. Dispos. 27:1350-1359 (1999).
11. P. Poulin, and F. P. Theil. A priori prediction of tissue: Plasma partition coefficients of drugs to facilitate the use of physiologically-based pharmacokinetic models in drug discovery. J. Pharm. Sci. 89:16-35 (2000).
12. P. Poulin, K. Schoenlein, and F. P. Theil. Prediction of adipose tissue: plasma partition coefficients for structurally unrelated drugs. J. Pharm. Sci. 90:436-447 (2001).
13. P. Poulin, and F. P. Theil. Prediction of pharmacokinetics prior to in vivo studies. 1. Mechanism-based prediction of volume of distribution. J. Pharm. Sci. 91:129-156 (2002a).
14. L. M. Berezhkovskiy. Volume of distribution at steady state for a linear pharmacokinetic system with peripheral elimination. J. Pharm. Sci. 93(6):1628-40 (2004).
15. T. Rodgers, D. Leahy, and M. Rowland. Physiologically based pharmacokinetic modeling 1: Predicting the tissue distribution of moderate-to-strong bases. J. Pharm. Sci. 94:1259-1276 (2005).
16. T. Rodgers, and M. Rowland. Physiologically based pharmacokinetic modeling 2: Predicting the tissue distribution of acids, very weak bases, neutrals and zwitterions. J. Pharm. Sci. 95(6):1238-57 (2006).
17. T. Rodgers, and M. Rowland. Mechanistic approaches to volume of distribution predictions: Understanding the processes. Pharm. Res. 24(5):918-33 (2007).
18. P. Poulin, and F. P. Theil. Prediction of pharmacokinetics prior to in vivo studies. II. Generic physiologically based pharmacokinetic models of drug disposition. J. Pharm. Sci. 91:1358-1370 (2002b).
19. F. P. Theil, T. W. Guentert, S. Haddad, and P. Poulin. Utility of physiologically based pharmacokinetic models to drug development and rational drug discovery candidate selection. Toxicol. Lett. 138:29-49 (2003).
20. N. Parrott, N. Paquereau, P. Coassolo, and T. Lave. An evaluation of the utility of physiologically based models of pharmacokinetics in early drug discovery. J. Pharm. Sci. 94:2327-2343 (2005).
21. F. A. Brightman, D. E. Leahy, G. E. Searle, and S. Thomas. Application of a generic physiologically-based pharmacokinetic model to the estimation of xenobiotic levels in rat plasma. Drug Metab. Dispos. 34:84-93 (2006a).
22. F. A. Brightman, D. E. Leahy, G. E. Searle, and S. Thomas. Application of a generic physiologically-based pharmacokinetic model to the estimation of xenobiotic levels in human plasma. Drug Metab. Dispos. 34:94-101 (2006b).
23. H. M. Jones, N. Parrott, K. Jorga, and T. Lave. A novel strategy for physiologically based predictions of human pharmacokinetics. Clin. Pharmacokinet. 45(5):511-542 (2006).
24. S. S. De Buck, V. K. Sinha, L. A. Fenu, M. J. Nijsen, C. E. Mackie, and R. A. H. J. Gilissen. Prediction of human pharmacokinetics using physiologically based modeling: A retrospective analysis of 26 clinically tested drugs. Drug Metab. Dispos. 35(10):1766-80 (2007a).
25. S. A. Peters. Evaluation of a generic physiologically based pharmacokinetic model for lineshape analysis. Clin. Pharmacokinet. 47(4):261-75 (2008).
26. M. Rowland, L. Balant, and C. Peck. Physiologically based pharmacokinetics in drug development and regulatory science: A workshop report (Georgetown University, Washington, DC, May 29-30, 2002). AAPS PharmSci. 6:E6 (2004).
27. B. Davies, and T. Morris. Physiological parameters in laboratory animals and humans. Pharm. Res. 10:1093-1095 (1993).
28. R. P. Brown, M. D. Delp, S. L. Lindstedt, L. R. Rhomberg, and R. P. Beliles. Physiological parameter values for physiologically based pharmacokinetic models. Toxicol. Ind. Health. 13:407-484 (1997).
29. R. L. Dedrick. Animal scale-up. J. Pharmacokinet. Biopharm. 1:435-461 (1973).
30. J. Mordenti. Man versus beast: Pharmacokinetic scaling in mammals. J. Pharm. Sci. 75:1028-1040 (1986).
31. T. Lave, R. Portmann, G. Schenker, A. Gianni, A. Guenzi, M. A. Girometta, and M. Schmitt. Interspecies pharmacokinetic comparisons and allometric scaling of napsagatran, a low molecular weight thrombin inhibitor. J. Pharm. Pharmacol. 51: 85-91 (1999b).
32. H. Tang, and M. Mayersohn. A novel model for prediction of human drug clearance by allometric scaling. Drug Metab. Dispos. 33: 1297-1303 (2005).
33. H. Tang, and M. Mayersohn. A global examination of allometric scaling for predicting tested drugs. Drug Metab. Dispos. 35:1766-1780 (2007).
34. I. Mahmood. Prediction of human drug clearance from animal data: Application of the rule of exponents and 'fu corrected intercept method' (FCIM). J. Pharm. Sci. 95(8):1810-1821 (2006).
35. V. K. Sinha, S. S. De Buck, L. A. Fenu, J. W. Smit, M. Nijsen, R. A. H. J. Gilissen, A. Van Peer, K. Lavrijsen, and C. E. Mackie. Predicting oral clearance in humans how close can we get with allometry? Clin. Pharmacokinet. 47(1):35-45 (2008).
36. W. L. Chiou, G. Robbie, S. M. Chung, T. C. Wu, and C. Ma. Correlation of plasma clearance of 54 extensively metabolized drugs between humans and rats: Mean allometric coefficient of 0.66. Pharm. Res. 15(9):1474-9 (1998).
37. J. B. Houston, and D. J. Carlile. Prediction of hepatic clearance from microsomes, hepatocytes, and liver slices. Drug Metab. Rev. 29:891-922 (1997).
38. K. Ito, and J. B. Houston. Comparison of the use of liver models for predicting drug clearance using in vitro kinetic data from hepatic microsomes and isolated hepatocytes. Pharm. Res. 21:785-792 (2004).
39. H. M. Jones, and J. B. Houston. Substrate depletion approach for determining in vitro metabolic clearance: Time dependencies in hepatocyte and microsomal incubations. Drug Metab. Dispos. 32:973-982 (2004).
40. R. P. Austin, P. Barton, S. L. Cockroft, M. C. Wenlock, and R. J. Riley. The influence of nonspecific microsomal binding on apparent intrinsic clearance, and its prediction from physicochemical properties. Drug Metab. Dispos. 30:1497-1503 (2002).
41. R. P. Austin, P. Barton, S. Mohmed, and R. J. Riley. The binding of drugs to hepatocytes and its relationship to physicochemical properties. Drug Metab. Dispos. 33:419-425 (2005).
42. D. Hallifax, and J. B. Houston. Binding of drugs to hepatic microsomes: Comment and assessment of current prediction methodology with recommendation for improvement. Drug Metab. Dispos. 34(4):724-26 (2006).
43. D. B. Turner, A. Rostami-Hodjegan, G. T. Tucker, and K. Rowland-Yeo. Prediction of non-specific hepatic microsomal binding from readily available physicochemical properties. 9th European ISSX Meeting June 4th-7th, Manchester, UK. (2006).
44. D. J. Carlile, K. Zomorodi, and J. B. Houston. Scaling factors to relate drug metabolic clearance in hepatic microsomes, isolated hepatocytes, and the intact liver: Studies with induced livers involving diazepam. Drug Metab. Dispos. 25:903-911 (1997).
45. Z. E. Wilson, A. Rostami-Hodjegan, J. L. Burn, A. Tooley, J. Boyle, S. W. Ellis, and G. T. Tucker. Inter-individual variability in levels of human microsomal protein and hepatocellularity per gram of liver. Br. J. Clin. Pharmacol. 56:433-440 (2003).
46. A. E. Barter, P. H. Beaune, A. R. Boobis, D. J. Carlile, R. J. Edwards, J. B. Houston, J. B. Lipscomb, O. R. Pelkonen, G. T. Tucker, and A. Rostami Hodjegan. Scaling factors for the extrapolation of in vivo microsomal protein and hepatocellularity per gram of liver. Curr. Drug. Metab. 8(1):33-45 (2007).
47. Y. Sawada, M. Hanano, Y. Sugiyama, H. Harashima, and T. Iga. Prediction of the volumes of distribution of basic drugs in humans based on data from animals. J. Pharmacokinet. Biopharm. 12:587-596 (1984).
48. L. X. Yu, and G. L. Amidon. A compartmental absorption and transit model for estimating oral drug absorption. Int. J. Pharm. 186:119-125 (1999).
49. B. Agoram, W. S. Woltosz, and M. B. Bolger. Predicting the impact of physiological and biochemical processes on oral drug bioavailability. Adv. Drug Deliv. Rev. 50 (Suppl 1):S41-67 (2001).
50. D. B. Turner, M. Jamei, G. T. Tucker, and A. Rostami-Hodjegan. Supersaturation properties of poorly soluble weak bases are key factors in determining drug absorption: A simulation study of nifedipine using the ADAM model (Simcyp v7.1). "EUFEPS & COST B25 Conference on Bioavailability and Bioequivalence: Focus on physiological factors and variability. October 1-2, 2007, Athens, Greece. (2007).
51. S. Willmann, W. Schmitt, J. Keldenich, and J. B. Dressman. A physiologic model for simulating gastrointestinal flow and drug absorption in rats. Pharm. Res. 20:1766-1771 (2003).
52. S. Willmann, W. Schmitt, J. Keldenich, J. Lippert, and J. B. Dressman. A physiological model for the estimation of the fraction dose absorbed in humans. J. Med. Chem. 47:4022-4031 (2004).
53. M. Germani, P. Crivori, M. Rocchetti, P. S. Burton, A. G. E. Wilson, M. E. Smith, and I. Poggesi. Evaluation of a basic physiologically based pharmacokinetic model for simulating the first-time-in-animal study. Eur. J. Pharm. Sci. 31:190-201 (2007).
54. S. S. De Buck, V. K. Sinha, L. A. Fenu, R. A. H. J. Gilissen, C. E. Mackie, and M. J. Nijsen. The prediction of drug metabolism, tissue distribution, and bioavailability of 50 structurally diverse compounds in rat using mechanism-based absorption, distribution, and metabolism prediction tools. Drug Metab. Dispos. 35:649-659 (2007b).
55. K. Ito, and J. B. Houston. Prediction of human drug clearance from in vitro and preclinical data using physiologically based and empirical approaches. Pharm. Res. 22:103-112 (2005).
56. Y. Naritomi, S. Terashita, A. Kagayama, and Y. Sugiyama. Utility of hepatocytes in predicting drug metabolism: Comparison of hepatic intrinsic clearance in rats and humans in vivo and in vitro. Drug Metab. Dispos. 31:580-588 (2003).
57. H. S. Brown, M. Griffin, and J. B. Houston. Evaluation of cryopreserved human hepatocytes as an alternative in vitro system to microsomes for the prediction of metabolic clearance. Drug Metab. Dispos. 35:293-301 (2007).
58. D. F. McGinnity, M. G. Soars, R. A. Urbanowicz, and R. J. Riley. Evaluation of fresh and cryopreserved hepatocytes as in vitro drug metabolism tools for the prediction of metabolic clearance. Drug Metab. Dispos. 32:1247-1253 (2004).
59. Y. Shibata, H. Takahashi, and Y. Ishii. A convenient in vitro screening method for predicting in vivo drug metabolic clearance using isolated hepatocytes suspended in serum. Drug Metab. Dispos. 28:1518-1523 (2000).
60. R. J. Riley, D. F. McGinnity, and R. P. Austin. A unified model for predicting human hepatic, metabolic clearance from in vitro intrinsic clearance data in hepatocytes and microsomes. Drug Metab. Dispos. 33:1304-1311 (2005).
61. S. E. Clarke, and P. Jeffrey. Utility of metabolic stability screening: Comparison of in vitro and in vivo clearance. Xenobiotica. 31:591-598 (2001).
62. K. Grime, and R. J. Riley. The impact of in vitro binding on in vitro - in vivo extrapolations, projections of metabolic clearance and clinical drug-drug interactions. Curr. Drug Metab. 7:251-264 (2006).
63. Y. Y. Lau, E. Sapidou, X. Cu, R. E. White, and K. C. Cheng. Development of a novel in vitro model to predict hepatic clearance using fresh, cryopreserved and sandwich-cultured hepatocytes. Drug. Metab. Dispos. 30:1446-1454 (2002).